<DOC>
	<DOCNO>NCT03003013</DOCNO>
	<brief_summary>Effect Biphasic Bone Graft Material ( BGM ) combination autologous platelet-rich fibrin ( PRF ) bone regeneration odontogenic maxillary cyst : randomized clinical trial</brief_summary>
	<brief_title>Effect Biphasic Bone Graft Material With Autologous Platelet-rich Fibrin Bone Regeneration Maxillary Cyst</brief_title>
	<detailed_description>Odontogenic cyst common form cystic lesion affect oral maxillofacial region . Their origin , mechanism growth , well treatment problem often discuss . Platelet rich fibrin ( PRF ) second generation platelet concentrate first develop France Choukron et al 2001 , prepare centrifuge autologous blood . It fibrin clot rich platelet without addition bovine thrombin , calcium chloride anticoagulant preparation thus eliminate risk associate use thrombin . Platelet rich fibrin derive natural progressive polymerization occur centrifugation . A progressive relatively slow polymerization mode may increase incorporation circulate cytokine fibrin mesh release relatively long-term controllable way turn help soft tissue heal accelerate bone regeneration . Blood Derivatives Enhancing Bone Regeneration : 1-Fibrin glue : It classically describe two component mixture concentrate fibrinogen factor XIII fibronectin add thrombin , calcium choloride inhibitor fibrinolysis form fibrin clot . Shortcomings : The risk transmission virus , like human immunodeficiency virus ( HIV ) . 2 . Autologous Fibrin Adhesives : The patient 's blood harvest 1:3 week intervention require separate one unit whole blood cell component plasma fraction use cryoprecipitate . Shortcomings : - Extremely long . - Complex protocol . 3 . Platelet rich plasma ( PRP ) : It modification type autologous fibrin adhesive require autologous blood collection immediate preoperative period processing centrifugation mixed bovine thrombine calcium chloride time application . Shortcomings : 1 . The use bovine thrombin put patient risk life -threating coagulopathies associate development antibody factor V , XI thrombin . 2 . Higher concentration thrombin impedes cell migration bone healing . 3 . It mediate early aspect bone repair . A variety treatment modality include use autogenous bone graft bone substitute material , guide tissue regeneration ( GTR ) use barrier membrane growth factor use stimulate bone regeneration mechanism.The drawback associate autogenous bone graft lead production large number alternative bone substitute material . Their biological behavior depend upon chemical composition physicochemical structure . Bone graft material include autograft , allograft , xenografts alloplasts . The osteoconductive hydroxyapatite graft material widely use enhance new bone regeneration . SYMBIOS® : Biphasic Bone Graft Material ( BGM ) resorbable inorganic bone form material granular form plant origin derive red marine algae . The chemical composition interconnect porous biological product similar inorganic part human bone . It composition 20 % hydroxyapatite ( HA ) 80 % β-tricalciumphosphate ( ß-TCP ) . Due high tricalcium- phosphate content product resorb significantly faster pure hydroxyapatite . The biphasic BGM biocompatible osteoconductive . The selection two grain size dependent defect . Growth factor represent area interest surgeon attempt modify enhance wind heal process tissue regeneration . However , Platelet-Rich Plasma ( PRP ) already use time hematologist transfusion prevention bleed episode patient severe thrombocytopenia . Uses PRF Over PRP : 1 . The improved mechanical property PRF conventional PRP translate biologic matrix easy handle implant awide variety tissue repair application . 2 . Platelets rich fibrin increase modulus elasticity . This property impart well pliability drapability , allow closely conform awide variety irregular surgical site surface similar split thickness skin auto graft . 3 . Platelet rich fibrin easily suture surgical site . Benefits study patient : - Treatment cystic lesion . - Enhancement bone regeneration . Benefits study clinician : The study provide new modality regeneration new bone cystic enucleation .</detailed_description>
	<mesh_term>Cysts</mesh_term>
	<criteria>Inclusion criterion 1 . Age range 15 : 60 year old . 2 . A maxillary odontogenic cyst large 3 cm size . Exclusion criteria 1 . A maxillary odontogenic cyst small 3 cm size . 2 . A mandibular odontogenic cyst . 3 . Non odontogenic cyst . 4 . Patients thrombotic risk factor take antiplatelets drug . 5 . Patients systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Odontogenic cyst</keyword>
	<keyword>Bone substitute material</keyword>
	<keyword>SYMBIOS®</keyword>
	<keyword>Platelets rich fibrin ( PRF )</keyword>
	<keyword>Bone regeneration</keyword>
</DOC>